News

American Association of Individual Investors6d
Which Is a Better Investment, Alvotech or Catalyst Pharmaceuticals, Inc. Stock?
Learn more about whether Alvotech or Catalyst Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Medpage Today on MSN2d
Alternative to Anti-VEGF Shows Safety, Efficacy in Diabetic Macular Edema
A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...
Ophthalmology Times2d
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...
MPR5d
High Dose Aflibercept Gets Priority Review for Retinal Vein Occlusion and Monthly Dosing
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for aflibercept injection 8mg for the treatment of macular edema following ...
Fierce Pharma6d
FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD
The FDA has sent Regeneron a complete response letter, rejecting its bid to stretch the administration of high-dose Eylea ...
Nasdaq5d
UNITY Biotechnology Reports Q1 2025 Financial Results and ASPIRE Study Data on UBX1325 for Diabetic Macular Edema
UNITY announced 24-week and partial 36-week topline data from our Phase 2b ASPIRE study in diabetic macular edema (DME) in the first quarter. DME patients treated with UBX1325 (foselutoclax ...
Investing3d
Earnings call transcript: Merck Q1 2025 beats EPS forecast
Merck & Co., Inc. reported its Q1 2025 earnings, surpassing analyst expectations with earnings per share (EPS) of $2.22 compared to the forecasted $2.14. The company also exceeded revenue ...